These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3982638)

  • 1. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
    Askenasy JJ; Yahr MD
    Neurology; 1985 Apr; 35(4):527-32. PubMed ID: 3982638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG; Markham CH; Treciokas LJ
    Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pergolide in the treatment of Parkinson's disease.
    Mear JY; Barroche G; de Smet Y; Weber M; Lhermitte F; Agid Y
    Neurology; 1984 Jul; 34(7):983-6. PubMed ID: 6539880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of REM rebound by Pergolide.
    Askenasy JJ; Yahr MD
    J Neural Transm; 1984; 59(2):151-9. PubMed ID: 6726217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease.
    Wailke S; Herzog J; Witt K; Deuschl G; Volkmann J
    Eur J Neurol; 2011 Apr; 18(4):590-6. PubMed ID: 20849470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease.
    Boyson SJ
    Neurology; 1990 Apr; 40(4):725. PubMed ID: 2320258
    [No Abstract]   [Full Text] [Related]  

  • 8. Further studies with pergolide in Parkinson disease.
    Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
    Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
    Yahr MD; Clough CG; Bergmann KJ
    Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
    [No Abstract]   [Full Text] [Related]  

  • 11. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
    Comella CL; Tanner CM; Ristanovic RK
    Ann Neurol; 1993 Nov; 34(5):710-4. PubMed ID: 8239565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 13. Parallel double-blind study of pergolide in Parkinson's disease.
    Jankovic J; Orman J
    Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
    [No Abstract]   [Full Text] [Related]  

  • 14. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
    Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F
    Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of parkinsonism.
    Calne DB; Teychenne PF; Pfeiffer RF
    Adv Exp Med Biol; 1977; 90():49-61. PubMed ID: 930750
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1985; 8(3):260-5. PubMed ID: 3899352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.